IL6 and COVID-19: Other IL-6 inhibitors under investigation include siltuximab (SYLVANT, NCT04322188) and fingolimod (NCT04280588) Nonetheless, several phase III and phase II RCTs remain in progress into at least September (REMDACTA, NCT04409262; NCT04372186, NCT04356937) and healthcare providers are still currently administering TCZ globally for advanced COVID-19 cases.